Core Viewpoint - DBV Technologies will participate in the EAACI Congress 2025, presenting new data on its VIASKIN® peanut patch and hosting a symposium focused on peanut allergy research [1][3][4] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN® patch technology [7][8] - The company aims to address food allergies through epicutaneous immunotherapy (EPIT™), which introduces microgram amounts of allergens to the immune system via the skin [7] Upcoming Presentations - At the EAACI Congress, DBV will present data from the EPITOPE open-label extension trial, highlighting reduced rates of reactions from accidental peanut consumption with the VIASKIN® peanut patch [2][4] - The APTITUDE study results will also be shared, evaluating the sensitivity, specificity, and safety of the VIASKIN® patch for diagnosing non-IgE mediated cow's milk allergy in infants [2][4] Symposium Details - The symposium titled "Peanut Allergy: Recent Research Highlights" will be co-chaired by Prof Gideon Lack and Prof Alexandra Santos, featuring discussions on the clinical relationship between allergists and food-allergic patients [3][5] - Presentations will include insights on epicutaneous immunotherapy and new clinical data related to peanut allergy [6][7] Clinical Data Highlights - Year 2 data from the EPITOPE trial will demonstrate real-world protective effects of the VIASKIN® peanut patch in peanut-allergic toddlers, showing further reductions in accidental peanut consumption-related reactions [4][7] - The APTITUDE study, despite early termination due to enrollment challenges, is viewed as a positive step in demonstrating the potential of the VIASKIN® patch in food allergy management [4][7]